Atara Biotherapeutics, Inc. Company Profile

03:50 EDT 22nd June 2018 | BioPortfolio

Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. The research of Atara and its family of companies is based on groundbreaking discoveries regarding the ability of activin, myostatin and other biological targets to change the course of disease progression. Atara has three novel biologics in development, including PINTA 745 (Phase 2) for protein energy wasting in end-stage renal disease, STM 434 (IND-ready) for ovarian cancer and other solid tumors, and NINA 842 (pre-clinical) for cancer-related cachexia. Atara and its family of companies were launched in 2012 by a proven team of drug developers, Amgen, and Kleiner Perkins Caufield & Byers. For more information, please visit

News Articles [210 Associated News Articles listed on BioPortfolio]

Atara's IND for therapy gets FDA nod

Atara Biotherapeutics' investigative new drug application for ATA188, which is indicated for the treatment of progressive mul -More- 

Atara Biotherapeutics gets FDA clearance to initiate two phase 3 clinical studies to assess tabelecleucel in patients with EBV+PTLD

Atara Biotherapeutics has received clearance from the US Food and Drug Administration (FDA) to initiate two phase 3 clinical studies with tabelecleucel (formerly known as ATA129) in patients with ritu...

Atara Biotherapeutics nets $120mm in FOPO

Atara Biotherapeutics Inc. (off-the-shelf T-cell immunotherapies for cancers, autoimmune diseases, and viral diseases developing using technology licensed from MSKCC) netted $120mm in a follow-on publ...

Follow-on offering brings in $150M for Atara

A follow-on offering brought in $150 million for Atara Biotherapeutics.  -More- 

Late-stage trials launched by Atara for immunotherapy candidate

Two late-stage studies, MATCH and ALLELE, will evaluate Atara Biotherapeutics' off-the-shelf T-cell immunotherapy tabelecleuc -More- 

Atara receives FDA approval for two Phase lll trials of tabelecleucel

Atara Biotherapeutics has secured approval from the US Food and Drug Administration (FDA) to begin two Phase lll clinical trials...Read More... The post Atara receives FDA approval for two Phase lll t...

Atara Biotherapeutics: Buy The Secondary

Atara Biotherapeutics: A Gift That Keeps On Giving

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]


Plasma Protein Fraction (Human) 5%, USPPlasmanate®


Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated


Albumin (Human) 5%, USPPlasbumin ®-5


Albumin (Human) 5%, USPPlasbumin ®-5


Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [18 Associated PubMed Articles listed on BioPortfolio]

Toward best practices in data processing and analysis for intact biotherapeutics by MS in quantitative bioanalysis.

Typically, quantitation of biotherapeutics from biological matrices by LC-MS is based on a surrogate peptide approach to determine molecule concentration. Recent efforts have focused on quantitation o...

Integrated BioTherapeutics.

Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.

The carbohydrate moieties on the polypeptide chains in most glycoprotein based biotherapeutics and their biosimilars play essential roles in such major mechanisms of actions as antibody-dependent cell...

Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out?

Protein tyrosine phosphatases (PTPs), of the receptor and non-receptor classes, are key signaling molecules that play critical roles in cellular regulation underlying diverse physiological events. Abe...

Population-specific design of de-immunized protein biotherapeutics.

Immunogenicity is a major problem during the development of biotherapeutics since it can lead to rapid clearance of the drug and adverse reactions. The challenge for biotherapeutic design is therefore...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [97 Associated Companies listed on BioPortfolio]

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. The research of Atara and it...

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

Talecris Biotherapeutics Holdings Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...

More Information about "Atara Biotherapeutics, Inc." on BioPortfolio

We have published hundreds of Atara Biotherapeutics, Inc. news stories on BioPortfolio along with dozens of Atara Biotherapeutics, Inc. Clinical Trials and PubMed Articles about Atara Biotherapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Atara Biotherapeutics, Inc. Companies in our database. You can also find out about relevant Atara Biotherapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Corporate Database Quicklinks

Searches Linking to this Company Record